VRAL- Up 50% Already- More 411

November 22, 2011
Volume XIII, Issue 109

Home Page : www.otcjournal.comEmail Questions or Comments To:
editor@otcjournal.com
To OTC Journal Members: 

This Is Really Big- DCA

 

I’ve done a little more research and I’m now more convinced than ever that yesterday’s penny stock idea- VRAL- has huge upside potential. I’ve looked into this DCA Cancer Therapy a bit further, and gotten a better understanding of the value.

This is my first big winner of the last few ideas, and those that acted on it yesterday are seeing the KACHING!!! Here’s the chart:

VRAL is now up a full 50% from yesterday’s entry level of $.02- as I said- it can be quite easy to notch nice gains in these really low priced ideas.

The market is starting to buzz about yesterday’s DCA announcement. I’ve done my research, and now understand why it’s so big. DCA- Dichloroacetate- is a metabolic disrupter. DCA is a non toxic chemical. It inteferes with the way cancer cells metabolize, and causes them to starve and subsequently die.

A number of major news outlets have covered DCA- accusing Big Pharma of ignoring the potential of DCA as it might be a simple way to treat cancer, and cost big pharma billions.

Evangelos Michelakis, a cancer researcher at the University of Alberta, discovered the compound and had encouraging results in the lab. Dr. Daniel Chang at Stanford Cancer Center is looking at is as well.

The compound was heretofore considered “unpatenable”- and therefore had limited commercial value.

Yesterday’s annoucement, for those that understand it, is huge. Dr. Karen Newell’s use of DCA has been officially granted a patent- US Patent office grant #8,071,646- to be issued on 12/6/2011.

This is huge stuff, particularly when you marry in Marshall Phelps, and advisor to VRAL. Phelps was formerly the Corporate Vice President at Microsoft in charge of Intellectual Property and Licensing.

Now that DCA has a patent, it a license or co development agreement with a major player has a lot of value. Hence, the surge in stock price.

Could be headed for much higher levels.

Home Page : www.otcjournal.com

Email Questions or Comments To:

editor@otcjournal.com

 


 

Refer
A Friend

If you find the OTC Journal informative
and profitable, please forward our newsletter alert service to like-minded
friends and associates who share similar market interests.


Ensure
Newsletter Delivery

To ensure newsletter delivery, you can add any additional email
addresses you may have to the OTC Journal Member List. Receiving the OTC
Journal Newsletter in multiple locations is the best way of making sure
you don’t miss the next investing or trading opportunity! For web based
email addresses, the OTC Journal recommends @yahoo.com or @aol.com for
timely and reliable email newsletter delivery.

Note: Your email address will be kept strictly confidential, and will not be shared with any other entity
for any purpose at any time. If you no longer wish to receive the OTC Journal,
simply follow the instructions located at the bottom of every OTC Journal
Newsletter Edition.

 


 

 

Disclaimer
DISCLAIMERThe OTC Journal Newsletter is an
electronic publication committed to providing our readers with useful information
on publicly traded companies. The Newsletter contracts with publicly traded
companies and receives compensation from them in the form of cash and sometimes
restricted securities as payment for publishing information and opinion
about the company and the trading market for their securities. Principals
of the Newsletter may also purchase or sell securities of the companies
in the open market from time to time. The positions that the Newsletter
or its principals maintain in securities of the companies are disclosed
here (click here) and should be considered in making an investment decision regarding
these companies securities.  The Newsletter may be deemed to have
a conflict of interest between its open market activity and positions in
these securities and the timing of and opinions expressed in its publications
concerning these companies.  The publications should not be considered
to be independent publications concerning the company.

All statements and opinions expressed
herein are those of the editors and are subject to change without notice.
The Newsletter maintains editorial control over its publications and the
companies profiled therein do not have any editorial rights concerning
the information published about them. A profile, description, or other
mention of a company in the newsletter is neither an offer nor solicitation
of an offer to buy or sell any securities mentioned. While we believe all
sources of information provided by us and contained in our publication
to be accurate and reliable, we cannot and do not guarantee the accuracy
of information we received from third parties. MarketByte LLC has been pledged fees of up to $10,000 for coverage of VRAL by Lake Group Media.

READERS  ARE ENCOURAGED TO DO
THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED IN
THIS PUBLICATION. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A
HIGH DEGREE OF RISK.

We encourage our readers to invest
carefully and read the investor information available at the web sites
of the Securities and Exchange Commission (“SEC”) at http://www.sec.gov
and/or the National Association of Securities Dealers (“NASD”) at http://www.finra.org.
We also recommend that you read the SEC advisory to investors concerning
Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm.
Readers can review all public filings by companies at the SEC’s EDGAR page.
The NASD has published information on how to invest carefully at its web
site.

The information found in this profile
is protected by the copyright laws of the united states and may not be
copied, or reproduced in any way without the expressed, written consent
of the editors of otcjournal.com.

 

You can unsubscribe
from this list at any time by Clicking
Here
. If you are having difficulty removing yourself or wish to change
your address please go to http://www.otcjournal.com/opt/?email=$subst(‘Recip.EmailAddr’).

Viral Genetics (VRAL) And Two Nobel Laureates

 

 

November 21, 2011
Volume XIII, Issue 108

Home Page : www.otcjournal.com

Email Questions or Comments To:
editor@otcjournal.com
 

To OTC Journal Members: 

Penny Stock Double Header

 

Another lousy day in the markets. But – wait- perhaps there is some heat out there!!! Investors are loving the little penny stocks- and here’s part II of this week’s double header. Another instance of a situation where you can control a lot of shares while taking only a little risk, and the tiniest of moves will yield very big percentage returns.

POSC was off to the races early- up 20% in the early going on good volume. The stock traded 1 million shares before I even got out of bed.

So, as the markets continue to be obsessed with the global inability of politicians to make the hard choices, we’ll be very happily looking at stocks that have almost no downside, and very strong upside where you can control a lot of stock.

When the markets are rough, investors love these little low priced stocks, and here’s another one in the biotech sector that appears to be ready to charge North.

Today’s idea has major news- it’s added another potential blockbuster therapy to its already extensive portfolio of potential home runs. If they just hit one of these therapies the upside from this level is incalculable and nearly infinite.

Where Can You Find This? Viral Genetics and Two Nobel Laureates

 

You might not believe this, but where can you find a 2 cent stock that boasts two Nobel Laureates on its advisory board- Dr. Luc Montagnier and Dr. Baruch Blumberg serve this little biotech story?

These kinds of companies make for the perfect low priced stocks to own- Why? Because tech breakthroughs in little stocks like this can lead to huge gains in stock price.

Viral Genetics (OTC PK: VRAL) is one of the companies working in a biotech field where major breakthroughs are widely anticipated by the industry.

TPT- Targeted Peptide Technology – is a medical field that is booming. The potential applications include HIV/AIDS, Lyme Disease, and Drug Resistant cancers. In fact, VRAL is already begun crafting its NDAs (New Drug Applications) with the FDA and has applied for early stage testing.

Six international early stage clinical trials have been completed- the trials demonstrated their VGV-X HIV therapy significantly reduced the viral load by 90% to 95% in many patients. Another words- their therapy makes the existing HIV therapies more effective.

With 40 million cases of HIV worldwide, the need to reduce the cost of HIV therapy is in high demand.

Today VRAL announced it’s added a new cancer therapy to its portfolio. Coming out of the University of Colorado (my Alma mater), VRAL today announced it has been granted the exclusive license to develop a compound known as DCA (dichloroacetic acid). DCA is an cancer therapy enhancement compound that accelerates the destruction of tumors without the debilitating side effects of chemotherapy or radiation- see news release below.

Small stocks like this are all about major breakthroughs- one strong announcement on any of the therapies they are working on, and you could see this stock trade up five fold from its low entry level today.

Another Perfect Chart- VRAL Poised To Move

 

The VRAL chart reveals another stock that has hit bottom and is in a rebound phase. A simple return to mid summer levels would yield over 50% return- but I’m looking for much more.

Let’s look at an information packed chart:

Over the last several weeks the multi month downtrend in this stock has reversed course, and the stock is now clearly headed for higher ground. I’m getting really fancy today, and providing a number of technical indicators that support this thesis.

First, after months of decline, it’s obvious the price has come off the oversold bottom- more than doubling over the last several weeks. The rate of incline is also increasing. Secondly, out of nowhere, volume has materialized on this story. Whenever you see this happen, there’s something going on out there people close to the company know about, and this can often be a precursor to a major breakthrough.

Thirdly- the accumulation/distribution line has turned up for the first time in months- at present, there are simply more buyers than sellers in this stock, which bodes well for higher levels.

Lastly is the MACD – The stock is trying very hard to break above the neutral line, and technicians watch this indicator for a surge above the zero line- as you can see, it’s just starting to turn up.

For 2 cents you can own a piece of a company that is developing therapies for a myriad of difficult diseases- HIV/AIDS, Lyme Disease, and a host of others. Human clinical trials have already been conducted on their HIV/AIDS therapy that proved they can get a good result in many cases.

This is a great shot for 2 cents. Someday, you’ll wake up and see this little 2 cent story trading at 10 cents and heading north on a major development. The market is pricing in something like that in the near future.

Here’s today’s news release for your review:

Granting of Patent Marks Milestone on Viral Genetics’ Path Toward Licensing Revenue

Viral Genetics (VRAL) reports that a patent under which it is exclusively licensed, will be granted for using a compound known as DCA to treat cancer. DCA (dichloroacetic acid) has emerged as a compound that accelerates the destruction of tumors without the deleterious and debilitating side effects associated with chemotherapy or radiation. This is the first patent granted for the use of DCA to treat cancer, and represents a significant milestone in the company’s growth.

The United States Patent and Trade Office has announced that the patent calling for the use of Dichloroacetate (DCA) to treat Cancer will be issued to the University of Colorado (CU) – and licensed exclusively to Viral Genetics – as a result of the invention filed by Viral Genetics’ Lead Scientist, Dr. M. Karen Newell Rogers during her tenure at CU. Newell Rogers originally filed the patent application in 2003, based on research work she and colleagues had done relating to “systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors”. Her work has resulted in the granting of patent number 8,071,645, which will issue on December 6, 2011.

Since filing the application, other companies and research entities, both in the US and internationally, have also done much work to validate and unlock the value inherent in utilizing DCA as a therapeutic agent. Over the last four years, extensive validating research has been performed that documents DCA as a potentially powerful cancer treatment. Dr. Newell Rogers is one of the scientific pioneers suggesting that agents, including DCA, that disrupt tumor specific metabolic pathways, will have value as novel cancer drugs and, as such, she is the first researcher to have a patent granted on its use in the battle against cancer.

Haig Keledjian, Viral Genetic’s CEO, said, “We have been strategically accumulating a significant and valuable portfolio of intellectual property rights around Dr. Newell’s core metabolic disruption science. As we take each step toward monetization of our IP portfolio, this patent, and many others that we anticipate will be granted, are expected to continue to create value for our shareholders. In concert with our legal team, we are setting in place the licensing and revenue strategy for the company from this IP portfolio.”

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports, including statements about its VG Energy, Inc. subsidiary. None of Viral Genetics’ drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world, nor are any non-pharmaceutical products of VG Energy, Inc. commercialized. While Viral Genetics believes that the forward-looking statements and underlying assumptions reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, the successful outcome of such studies or tests, or the successful commercialization of VG Energy, Inc.’s non-pharmaceutical products. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.

Read the full story at http://www.prweb.com/releases/2011/11/prweb8981224.htm

PRWeb.com

Press Releases: VRAL

Home Page : www.otcjournal.com

Email Questions or Comments To:

editor@otcjournal.com

 


 

Refer
A Friend

If you find the OTC Journal informative
and profitable, please forward our newsletter alert service to like-minded
friends and associates who share similar market interests.


Ensure
Newsletter Delivery

To ensure newsletter delivery, you
can add any additional email
addresses you may have to the OTC Journal Member List. Receiving the OTC
Journal Newsletter in multiple locations is the best way of making sure
you don’t miss the next investing or trading opportunity! For web based
email addresses, the OTC Journal recommends @yahoo.com or @aol.com for
timely and reliable email newsletter delivery.

Note: Your email address will
be kept strictly confidential, and will not be shared with any other entity
for any purpose at any time. If you no longer wish to receive the OTC Journal,
simply follow the instructions located at the bottom of every OTC Journal
Newsletter Edition.

 


 

 

Disclaimer
DISCLAIMER

The OTC Journal Newsletter is an
electronic publication committed to providing our readers with useful information
on publicly traded companies. The Newsletter contracts with publicly traded
companies and receives compensation from them in the form of cash and sometimes
restricted securities as payment for publishing information and opinion
about the company and the trading market for their securities. Principals
of the Newsletter may also purchase or sell securities of the companies
in the open market from time to time. The positions that the Newsletter
or its principals maintain in securities of the companies are disclosed
here (click
here
) and should be considered in making an investment decision regarding
these companies securities.  The Newsletter may be deemed to have
a conflict of interest between its open market activity and positions in
these securities and the timing of and opinions expressed in its publications
concerning these companies.  The publications should not be considered
to be independent publications concerning the company.

All statements and opinions expressed
herein are those of the editors and are subject to change without notice.
The Newsletter maintains editorial control over its publications and the
companies profiled therein do not have any editorial rights concerning
the information published about them. A profile, description, or other
mention of a company in the newsletter is neither an offer nor solicitation
of an offer to buy or sell any securities mentioned. While we believe all
sources of information provided by us and contained in our publication
to be accurate and reliable, we cannot and do not guarantee the accuracy
of information we received from third parties. MarketByte LLC has been pledged fees of up to $!0,000 by Lake Group Media for coverage of Viral Genetics.

READERS  ARE ENCOURAGED TO DO
THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED IN
THIS PUBLICATION. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A
HIGH DEGREE OF RISK.

We encourage our readers to invest
carefully and read the investor information available at the web sites
of the Securities and Exchange Commission (“SEC”) at http://www.sec.gov
and/or the National Association of Securities Dealers (“NASD”) at http://www.finra.org.
We also recommend that you read the SEC advisory to investors concerning
Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm.
Readers can review all public filings by companies at the SEC’s EDGAR page.
The NASD has published information on how to invest carefully at its web
site.

The information found in this profile
is protected by the copyright laws of the united states and may not be
copied, or reproduced in any way without the expressed, written consent
of the editors of otcjournal.com.


Compensation and Other Disclosures

The content of this message is published by Imperial Consulting Network Inc.  and sent to select email lists through Lake Group Media, Inc. (“Lake”) to provide readers with information on selected publicly traded companies. Factual information is obtained from public filings and other sources deemed to be reliable; however, neither Imperial Consulting Network Inc.  nor Lake takes responsibility for verifying the accuracy of such information and they make no representation that such information is accurate or complete. Certain of the statements in this Update may be considered forwarded looking statements. Imperial Consulting Network Inc.  and Lake make no representation and provide no assurance or guaranty that such forward looking statements will prove to be accurate. See the company’s filings with the Securities and Exchange Commission for factors that may cause results to be significantly different. Statements of opinion and belief are those of the authors and/or editors of this Update, and are based solely upon the information possessed by such authors and/or editors; no inference should be drawn that such authors or editors have any special or greater knowledge about the company or companies profiled or any particular expertise in the industries or markets in which the profiled company or companies compete. The reader should verify all claims and complete his own due diligence before investing in any securities of the profiled company or companies. Neither Imperial Consulting Network Inc. , Lake, nor anyone involved in the publication or dissemination of this Update is a registered investment adviser or broker/dealer. Imperial Consulting Network Inc.  and Lake make no recommendation that the purchase of securities of the company or companies profiled in this Update are suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the company or companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree! of risk. An investor in such securities should be prepared and able to bear a loss of his or her entire investment. Nothing in this Update should be construed as an offer or solicitation to buy or sell any securities of any profiled company. Lake has been retained to provide direct marketing services for the company profiled in this Update and receives compensation for those services. Further, Lake and its employees and affiliates may own, or may purchase and sell, securities of the company or companies profiled. Lake undertakes no obligation to inform readers about the ownership or trading activities of it or its employees or affiliates in the securities of the profiled company or companies. Lake has the following compensation arrangements with the company or companies profiled in this Update: Lake receives an advertising fee ranging from $1,000 to $100,000 for each direct marketing list recommended and ordered for the dissemination of this Update.

You can unsubscribe
from this list at any time by Clicking
Here
. If you are having difficulty removing yourself or wish to change
your address please go to http://www.otcjournal.com/opt/?email=$subst(‘Recip.EmailAddr’).

A Smokin’ Hot Penny Stock: Positron (POSC)

 

November 20, 2011
Volume  XIII, Issue 107

Home Page : www.otcjournal.com

Email Questions or Comments To:
editor@otcjournal.com
 

To OTC Journal Members: 

A Smokin’ Hot Penny Stock: Positron (POSC)

 

Did you wake up today worrying about the global supply of medical radioisotopes? I know I didn’t. Strontium-82 and other medical radionuclides were not the subjects of concern this Sunday morning.

I know it wasn’t foremost on my mind. However, it’s on the mind of penny stock lovers as one small company is making an aggressive move into this sector. One day last week this stock traded 400,000 shares. The next day it traded 37 million shares.

Now, that’s some interest. Oh, and by the way, the day it traded 37 million shares, the stock was up 150% during intraday trading.

Now, I don’t know a lot about medical radionuclides, but I’ve done a little research, and this is cutting edge medical stuff. Here’s the scoop:

Radionuclides are small amounts of nuclear material that can be combined with other elements to form pharmaceutical chemical compounds. These compounds can then be admistered to a patient, and then these nuclear materials attach themselves to diseased tissues internally.

The patient is then treated with a laser targeted radiation- allowing for the destruction of diseased tissues and/or cancerous tumors.

Here’s how this therapy would compare to a military operation. Imagine the Navy Seals sneaking into a Taliban compound and hiding a little homing device. Our Navy ship could than launch a missile, guided by the homing device. The net result- Boom- a bunch of dead bad guys.

Formerly unknown, but now red hot Positron Corp (OTC BB: POSC) announced last week it will be acquiring Manhattan Isotope of Lubbock, Texas. The acquisition is expected to close January 2, 2012.

Apparently, Manhattan Isotope produces the medical radioisotope strontium-82. As a follow up last week, POSC announced Manhattan Isotope will collaborate with French based Arronax to further develop these radio isotopes.

The stock market has loved this series of announcements, and the stock is red hot.

Here’s why it’s time to catch the next run.

Positron (OTC BB: POSC): A Perfect Chart

 

What to see a chart with a perfect entry level?

If you see a stock breakout, and you want to get on board, but you don’t want to buy at the top, use Fibonacci Retracements. Fibonacci, a 12th Century mathematician, identified certain ratios that constantly re occur in nature.

One of the key numbers in the Fibonacci Ratios is 61.8%- measure your arm sometime. If you let your arm hang on the side of your body, I’ll bet then end of your fingers is very close to 61.8% of your height from the ground.

61.8% retracements are ideal entry level. If you take your position, and the stock wants to fall farther, just sell and get out. That stock is not going to bounce.

It might choose to trade sideways for a day or two. If, within a reasonable amount of time, it doesn’t head back up, you know it’s not going to. A 61.8% retracement is about the lowest risk entry point you’ll find for a hot stock.

Here’s the POSC chart. Note early last week the stock was trading at 1.1 cents very quietly. Boom- the news takes the stock from 400k shares one day to nearly 40 million the next day.

Any surge like that is going to be met with a pullback. It’s normal and natural. It’s also going to draw attention, so those that felt they missed the first move might start piling in on the pullback.

The perfect 61.8% retracement from last week’s action for POSC is $.0141- or 1.4 cents. Friday’s last trade was 1.36 cents, so close enough for me.

It’s worth noting a move just to 2 cents yields a 47% return over Friday’s close. Need I say more.

As I said- a perfect little penny stock with a perfect entry level. The odds are in your favor at the open tomorrow. You can own a lot of stock risking very little capital.

Home Page : www.otcjournal.com

Email Questions or Comments To:

editor@otcjournal.com

 


 

Refer
A Friend

If you find the OTC Journal informative
and profitable, please forward our newsletter alert service to like-minded
friends and associates who share similar market interests.


Ensure
Newsletter Delivery

To ensure newsletter delivery, you
can add any additional email
addresses you may have to the OTC Journal Member List. Receiving the OTC
Journal Newsletter in multiple locations is the best way of making sure
you don’t miss the next investing or trading opportunity! For web based
email addresses, the OTC Journal recommends @yahoo.com or @aol.com for
timely and reliable email newsletter delivery.

Note: Your email address will
be kept strictly confidential, and will not be shared with any other entity
for any purpose at any time. If you no longer wish to receive the OTC Journal,
simply follow the instructions located at the bottom of every OTC Journal
Newsletter Edition.

 


 

 

Disclaimer
DISCLAIMER

The OTC Journal Newsletter is an
electronic publication committed to providing our readers with useful information
on publicly traded companies. The Newsletter contracts with publicly traded
companies and receives compensation from them in the form of cash and sometimes
restricted securities as payment for publishing information and opinion
about the company and the trading market for their securities. Principals
of the Newsletter may also purchase or sell securities of the companies
in the open market from time to time. The positions that the Newsletter
or its principals maintain in securities of the companies are disclosed
here (click
here
) and should be considered in making an investment decision regarding
these companies securities.  The Newsletter may be deemed to have
a conflict of interest between its open market activity and positions in
these securities and the timing of and opinions expressed in its publications
concerning these companies.  The publications should not be considered
to be independent publications concerning the company.

All statements and opinions expressed
herein are those of the editors and are subject to change without notice.
The Newsletter maintains editorial control over its publications and the
companies profiled therein do not have any editorial rights concerning
the information published about them. A profile, description, or other
mention of a company in the newsletter is neither an offer nor solicitation
of an offer to buy or sell any securities mentioned. While we believe all
sources of information provided by us and contained in our publication
to be accurate and reliable, we cannot and do not guarantee the accuracy
of information we received from third parties. MarketByte LLC has been pledged a fee of up to $10,000 buy EEA inc for coverage of Positron.

READERS  ARE ENCOURAGED TO DO
THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED IN
THIS PUBLICATION. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A
HIGH DEGREE OF RISK.

We encourage our readers to invest
carefully and read the investor information available at the web sites
of the Securities and Exchange Commission (“SEC”) at http://www.sec.gov
and/or the National Association of Securities Dealers (“NASD”) at http://www.finra.org.
We also recommend that you read the SEC advisory to investors concerning
Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm.
Readers can review all public filings by companies at the SEC’s EDGAR page.
The NASD has published information on how to invest carefully at its web
site.

The information found in this profile
is protected by the copyright laws of the united states and may not be
copied, or reproduced in any way without the expressed, written consent
of the editors of otcjournal.com.

 

You can unsubscribe
from this list at any time by Clicking
Here
. If you are having difficulty removing yourself or wish to change
your address please go to http://www.otcjournal.com/opt/?email=$subst(‘Recip.EmailAddr’).

Attention Penny Stock Lovers

 
November 17, 2011
Volume      XIII, Issue 107

Home Page : www.otcjournal.comEmail Questions or Comments To:
editor@otcjournal.com

To OTC Journal Members: 

A Bit of A Snore

 

Shakespeare said it best- so far, Much Ado About Nothing.

Fledgling oil exploration company American Liberty (OREO), with the exception of one brief blip down, has been a bit of a snore.

$1.20 was about the entry level, and $1.20 is about where the stock is trading today. On Tuesday it briefly blipped down to about $1, and then quickly rebounded.

Since my SSL was about $1, perhaps some of you got “Whipsawed” in the stock- meaning bought, sold on the drop, then watched it quickly bounce. Perhaps some of you didn’t.

Volume has subsided substantially, and the stock has so far been pegged with 5 cents of the entry level.

I hope there’s a another leg up in this stock in the not too distant future. In the meantime, stay disciplined on your stops and your targets.

Honorable Mention Sagebrush Gold (OTC BB: SAGE)

 

Nevada based Sagebrush Gold (SAGE) gets honorable mention for recent price performance.

I covered SAGE back on 9/25 at an entry level of $1.03. The stock hit $1.30 in a couple of trading days, but then headed south for 6 out of 8 days to end up making a bottom at about $.45.

However, since finding its bottom, SAGE has rebounded handsomely- proving that you have to keep watching these stocks as you never know when opportunities will arise.

Here’s how the stock has behaved of late:

Off the bottom of $.45, the stock has nearly doubled in the last 15 trading days. Moral of the story- keep following these things. One never knows.

Attention Penny Stock Lovers

 

Since it seems to be a little tougher to make money in penny stocks, I believe I’m going to feature one or two penny/penny stocks. These stocks are so low they almost can’t go any lower.

It’s worth noting- if you pick up a 1 cent stock and it goes to 1.5 cents, the ROI is no different than a $10 stock going to $15, or a $100 stock going to $150.

Look for a “can’t go any lower” idea soon. If you love a good old fashioned true penny stock, you might like this one.

Home Page : www.otcjournal.com

Email Questions or Comments To:

editor@otcjournal.com

 


 

Refer
A Friend

If you find the OTC Journal informative
and profitable, please forward our newsletter alert service to like-minded
friends and associates who share similar market interests.


Ensure
Newsletter Delivery

To ensure newsletter delivery, you
can add any additional email
addresses you may have to the OTC Journal Member List. Receiving the OTC
Journal Newsletter in multiple locations is the best way of making sure
you don’t miss the next investing or trading opportunity! For web based
email addresses, the OTC Journal recommends @yahoo.com or @aol.com for
timely and reliable email newsletter delivery.

Note: Your email address will
be kept strictly confidential, and will not be shared with any other entity
for any purpose at any time. If you no longer wish to receive the OTC Journal,
simply follow the instructions located at the bottom of every OTC Journal
Newsletter Edition.

 


 

 

Disclaimer
DISCLAIMERThe OTC Journal Newsletter is an
electronic publication committed to providing our readers with useful information
on publicly traded companies. The Newsletter contracts with publicly traded
companies and receives compensation from them in the form of cash and sometimes
restricted securities as payment for publishing information and opinion
about the company and the trading market for their securities. Principals
of the Newsletter may also purchase or sell securities of the companies
in the open market from time to time. The positions that the Newsletter
or its principals maintain in securities of the companies are disclosed
here (click
here
) and should be considered in making an investment decision regarding
these companies securities.  The Newsletter may be deemed to have
a conflict of interest between its open market activity and positions in
these securities and the timing of and opinions expressed in its publications
concerning these companies.  The publications should not be considered
to be independent publications concerning the company.

All statements and opinions expressed
herein are those of the editors and are subject to change without notice.
The Newsletter maintains editorial control over its publications and the
companies profiled therein do not have any editorial rights concerning
the information published about them. A profile, description, or other
mention of a company in the newsletter is neither an offer nor solicitation
of an offer to buy or sell any securities mentioned. While we believe all
sources of information provided by us and contained in our publication
to be accurate and reliable, we cannot and do not guarantee the accuracy
of information we received from third parties.

READERS  ARE ENCOURAGED TO DO
THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED IN
THIS PUBLICATION. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A
HIGH DEGREE OF RISK.

We encourage our readers to invest
carefully and read the investor information available at the web sites
of the Securities and Exchange Commission (“SEC”) at http://www.sec.gov
and/or the National Association of Securities Dealers (“NASD”) at http://www.finra.org.
We also recommend that you read the SEC advisory to investors concerning
Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm.
Readers can review all public filings by companies at the SEC’s EDGAR page.
The NASD has published information on how to invest carefully at its web
site.

The information found in this profile
is protected by the copyright laws of the united states and may not be
copied, or reproduced in any way without the expressed, written consent
of the editors of otcjournal.com.

 

You can unsubscribe
from this list at any time by Clicking
Here
. If you are having difficulty removing yourself or wish to change
your address please go to http://www.otcjournal.com/opt/?email=$subst(‘Recip.EmailAddr’).

Nevada Black Gold- American Liberty (OREO)

 

 

November 13, 2011
Volume XIII, Issue 105

Home Page : www.otcjournal.com

Email Questions or Comments To:
editor@otcjournal.com
 

To OTC Journal Members: 

Black Gold, Texas Tea

 

Ok- They have Texas Tea in Nevada as well. How many readers are old enough to remember the Beverly Hillbillies TV show starring Buddy Ebsen as Jed Clampett?- the reluctant hillbilly turned Beverly Hills millionaire when they discover oil on his mountain property.

“One Day He Was Shooting At Some Food, and up From the Ground Come A Bubbling Crude”.

The Beverly Hillbillies sitcom ran on CBS from 1962 to 1971- coincidentally it was near the end of the show’s run when oil prices went berserk for the first time in the modern era.

Not many people know this, but oil actually sold for over $70 a barrel in 1869- when it was first drilled for. Conventional thinking in 1869 believed there was no way you could stick a drill bit in the ground and find oil. Once drilling started as the technology was available, oil spent the next 100 years between $10 and $20 per barrel as it was easily found in the US.

It was the decade of the 70′s that saw the first major oil shortage, raging inflation, and out of control pricing. Prices started the 70′s decade at about $25 per barrel, and ended at $70 per barrel. By the 70′s we had evolved to a dependence on Middle Eastern oil, and when there were shortages and embargoes, oil prices went berserk.

It was the oil shortages of the 70′s that caused Brazil to go down a path of long term energy independence. We, in the US, instead chose to buddy up to the Shah of Iran and the King of Saudi Arabia to insure our oil supplies.

The Brazilians were smart enough to develop a sensible approach to Ethanol as a fuel additive. You see- in the US we have government mandated Ethanol production in all of our gasoline. This is a giant scam on the American people costing us billions. Our Ethanol industry uses corn to derive the ethanol, and the yields don’t work. It’s a flawed model. It takes far too much corn to produce the required ethanol, and we subsidize the ethanol and corn growers with tax dollars.

The demand for ethanol drives up the price of corn, which in turn drives up the price of feeding livestock, which of course drives up the price of food.

The Ethanol scam is left over from the Bush Administration’s buddying up to Archer Daniels Midland (NYSE: ADM), one of GW’s largest campaign contributors.

Ethanol works in Brazil because it is derived from sugar cane. Ethanol yields from sugar cane are nearly 10 times that of corn, and that model makes economic sense. During 2008 Ford Motor prospered selling its “Flex” vehicle lines in South America while GM was dying. Those vehicles were designed to run on much higher levels of Ethanol.

When the price of oil retreated in the 80′s and 90′s we lost our focus on energy independence. Brazil did not, and look where it got us.

With oil demand ever growing out of Emerging Economies, we are now refocusing on developing domestic supplies.

Demand from emerging nations has oil over $100 per barrel once again, and there’s a lot of rhetoric in the election speak about developing US resources aggressively again. There are 3 states that have very lenient drilling policies- Texas, North Dakota, and Nevada. Looking for work? – I’ve read there’s a need for 2,000 workers today in West North Dakota as the Baaken Shale is expected to eventually add 2 million barrels a day to domestic oil production.

I believe the small oil and gas exploration companies are going to get hot again, and new entrants into the field will be greeted by the market with enthusiasm. So far, on small oil and gas companies I’m 3 out of 4.

I’ve covered three companies in the sector in the last year. Field Point Petroleum (AMEX: FPP) was a big win- trading from $3.00 about a year ago today to $5.50 by March for a 83% gain in 5 months.

Imperial Resources (OTC BB: IPRC) (4/17) was a big win as well. Introduced last May at $.40, the stock found the $.70 level twice by June- yielding a 75% return.

How about Eagle Ford Energy (OTC BB: EFRDF)? $1 in May to $1.80 in June- another 80% win.

Bering Exploration (OTC BB: BERX) was my one winner and loser. First covered on March 31st, the stock cooperated in the short term running from $.80 to $1.60 by the end of April providing OTC Journal readers with a cool 100% gain in the first month.

I stuck with that one a little too long, and it reversed course on me and became a loser.

The track record in the last year is 4 big wins in the sector, and 1 loss. Hence the need to stick with the SSLs- Suggested Stop Losses- minimize the losses, and you are way ahead.

As I pointed out in yesterday’s edition- you have the pole position on this new idea- it’s never traded and no one knows about it. When it becomes a “Crowded Trade”, you can be a seller for a strong profit.

Black Gold in Nevada: American Liberty (OTC BB: OREO)

 

OREO is the new kid on the block, and as promised you are getting the absolute first look.

I’m not going to put up a chart because there’s nothing to see- this stock has never traded. The stock traded a few shares at $1.25, and that’s it. Of course, as I pointed out in yesterday’s edition, there was a time when RAYS had traded zero at $1.25- when the volume came in, it traded to $2.40 in a month before crashing. The early entrants on that ride made a lot of money.

Based in Bakersfield, California, OREO has acquired the rights to drill on two large claims in Nevada: The Gabbs Valley prospect, and the Kibby Flat prospect.

Both of these properties were first looked at and evaluated in 2008. Both were found to have extremely high probabilities for profitable drilling, but the economic climate in 2008 caused the discoveries to be temporarily shelved.

Their Kibby Flats prospect is estimated to contain as much as 669 million barrels of recoverable oil spanning 7270 acres of land.

Their Gabbs Valley prospect is estimated to contain 4+ billion barrels of oil over 26,000 acres.

To learn more about the company and their plans, visit their web site at http://www.americanlibertypetro.com/website.php.

You want to be positioned ahead of certain events in a stock like this. The “Thrill of the Drill” will drive this stock higher in the near future as the company prepares to do some test drilling. Remember, as we learned in past editions- it’s the prospect of doing the test drilling that will push up the price- not the actual event.

You want to be in ahead of the crowd.

Since it’s impossible to make any sort of technical call on this one, set your SSL 15% below your entry level. That seems like a reasonable risk to take.

Let’s look to own this one in the $1.25 range- but you will have to use your judgement when it begins to trade at the open. A gap much above $1.25 should be avoided. $1.30 to- $1.35 should be the max. Based on past experience, I’m looking for the stock to go to $2, but I’ll make adjustments when it begins to trade in earnest, and a chart develops.

Let the fun begin.

Home Page : www.otcjournal.com

Email Questions or Comments To:

editor@otcjournal.com

 


 

Refer
A Friend

If you find the OTC Journal informative
and profitable, please forward our newsletter alert service to like-minded
friends and associates who share similar market interests.


Ensure
Newsletter Delivery

To ensure newsletter delivery, you
can add any additional email
addresses you may have to the OTC Journal Member List. Receiving the OTC
Journal Newsletter in multiple locations is the best way of making sure
you don’t miss the next investing or trading opportunity! For web based
email addresses, the OTC Journal recommends @yahoo.com or @aol.com for
timely and reliable email newsletter delivery.

Note: Your email address will
be kept strictly confidential, and will not be shared with any other entity
for any purpose at any time. If you no longer wish to receive the OTC Journal,
simply follow the instructions located at the bottom of every OTC Journal
Newsletter Edition.

 


 

 

Disclaimer
DISCLAIMER

The OTC Journal Newsletter is an
electronic publication committed to providing our readers with useful information
on publicly traded companies. The Newsletter contracts with publicly traded
companies and receives compensation from them in the form of cash and sometimes
restricted securities as payment for publishing information and opinion
about the company and the trading market for their securities. Principals
of the Newsletter may also purchase or sell securities of the companies
in the open market from time to time. The positions that the Newsletter
or its principals maintain in securities of the companies are disclosed
here (click
here
) and should be considered in making an investment decision regarding
these companies securities.  The Newsletter may be deemed to have
a conflict of interest between its open market activity and positions in
these securities and the timing of and opinions expressed in its publications
concerning these companies.  The publications should not be considered
to be independent publications concerning the company.

All statements and opinions expressed
herein are those of the editors and are subject to change without notice.
The Newsletter maintains editorial control over its publications and the
companies profiled therein do not have any editorial rights concerning
the information published about them. A profile, description, or other
mention of a company in the newsletter is neither an offer nor solicitation
of an offer to buy or sell any securities mentioned. While we believe all
sources of information provided by us and contained in our publication
to be accurate and reliable, we cannot and do not guarantee the accuracy
of information we received from third parties. MarketByte LLC has been paid a fee of $10,000 for coverage of American Libety by Winning Media.

READERS  ARE ENCOURAGED TO DO
THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED IN
THIS PUBLICATION. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A
HIGH DEGREE OF RISK.

We encourage our readers to invest
carefully and read the investor information available at the web sites
of the Securities and Exchange Commission (“SEC”) at http://www.sec.gov
and/or the National Association of Securities Dealers (“NASD”) at http://www.finra.org.
We also recommend that you read the SEC advisory to investors concerning
Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm.
Readers can review all public filings by companies at the SEC’s EDGAR page.
The NASD has published information on how to invest carefully at its web
site.

The information found in this profile
is protected by the copyright laws of the united states and may not be
copied, or reproduced in any way without the expressed, written consent
of the editors of otcjournal.com.

 

You can unsubscribe
from this list at any time by Clicking
Here
. If you are having difficulty removing yourself or wish to change
your address please go to http://www.otcjournal.com/opt/?email=$subst(‘Recip.EmailAddr’).

Oil Is Back

November 12, 2011
Volume
XIII, Issue 104

Home Page : www.otcjournal.com

Email Questions or Comments To:
editor@otcjournal.com

 

To OTC Journal Members: 

How It Really Works

 

I’ve been watching- Watching for two factors to come together. They’ve come together, and it’s time to make some money.

First, I’ve been watching for the market to shake off its obsession with every little move out of Europe. I suspect the issues in Europe are going to take some time to solve, and I’m not even sure if the resolution will be favorable for world markets. I know the ECU is putting its best foot forward, but the politicians are getting in the way. Sanity will prevail.

So, as the loud noise out of Europe quiets a bit, markets are coming back, and penny stocks are starting to rip to the upside. I’ve been reluctant to do much of late since the last two of my famous “Sunday” ideas were down slightly, but now I believe it’s time to get engaged and busy again.

As my long term readers know, I pride myself on having the pole position on these ideas- you learn about them before anyone.

Here’s a inside scoop for you. The best penny stocks trade significant volume because there are very robust “awareness” campaigns put in place. The typical penny stock investor watches a stock run up 25% to 40% on big volume, then greed gets the better of that investor, and he (or she) finally jumps in at the top, only to watch as the stock peaks in a day or two, and heads back down. This is the investor who ends up “holding the burning match” down to his fingers.

I pride myself on getting you in ahead of the crowd. Very often this pays off for us- here’s a list:

  • AAST (6/6): 73%
  • GCLL (8/25): 118%
  • TKDN (9/12): 31%
  • AAGC (9/13): 26%
  • IPRC (4/17): 61%

Being first doesn’t always pay off to the upside, but it always helps protect your downside risk. Here’s the scoop.

When a penny stock gets hot and starts trading huge volume, it becomes what pros call a “Crowded Trade”. As the stock works its way higher, the greed factor kicks in, and buyers all get on the same crowded trade at the same time.

However, eventually the stock peaks, and everyone tries to get off the moving train at the same time. The result is a train wreck. Here’s a chart of a recent highly promoted and great trading stock- for a time.

RAYS has been on every penny stock trader’s radar screen for the last 3 weeks. As you can see, the stock started trading up in Mid October, and moved from about $1.20 to a high of $2.50 in a month.

Look what happened to the stock when every investors tried to get out the door of that speeding train all at once. The stock traded down below its starting point in one day on huge volume.

Here’s the point. If someone didn’t advise you to get in RAYS in the first few days, unless you were really nimble, you got killed in this one.

When I deliver you a Sunday idea, it’s at the front end, and you’re the first to know the stock that millions will learn about in the coming weeks.

It’s worked very well for us in the past as you can see from the list above. However, you might not realize what really works about this strategy. You have downside protection. You’re in before the train gets crowded, and therefore if the stock trades the other way, it won’t be a violent crash and you can get out with a minimal loss.

This requires you to have discipline and stick to my SSLs (suggested stop loss). If you have a brokerage account that won’t allow you to file a stop loss the moment you trade into a stock, get a different brokerage firm.

I use eTrade.com, and I have no problem filing conditional orders for everything I own. Now- a little preview of this week’s coming attraction.

Oil Is Back!!!

 

In case you haven’t noticed, world markets are shaking off the mega fears of the August/September madness, and there’s a kind of stealth bull market going on in global equities. It’s not a raging bull, but there’s a perception economies are definitely getting better.

There’s no better indicator of the perception economies are coming back than the price of oil. The implication is strong economies need more oil.

Have you looked at a chart of oil lately?

This is the Goldman Sachs Oil index. If you want to know what the market really believes about the health of the global economy, watch this index. It is probably the best leading indicator of the perception of global financial health, and the price of oil is super sensitive to perception of global supply and demand.

As you can see, oil has been climbing steadily and rapidly since the big blow off in mid October.

I’ve put the 50 Day (blue) and 200 Day (red) moving averages in the chart. The level of this index is above both of those measures, suggesting oil is in both a short and long term up trend.

It will be volatile as the market over reacts to the news out of Europe. However, this is not a chart that reflects some sort of massive global slow down. This is a chart that suggests demand will be growing faster that supply in the oil patch.

That’s why I believe it’s time to look at some micro cap domestic oil ideas again. The sector did extremely well last spring and into the summer, and I expect the market will start embracing the nimble, smaller, oil exploration and production companies once again.

Here’s the big news- A new Sunday idea fell into my lap, and you’ll learn about it tomorrow. No one knows about this company yet, and you’ll have the pole position out in front of a major awareness campaign.

Our last big winner in this sector was Imperial Resources (IPRC)- introduced at $.49, IPRC delivered a 61% gain.

Perhaps we have another of those on the horizon. Stay tuned for tomorrow’s new idea.

Home Page : www.otcjournal.com

Email Questions or Comments To:

editor@otcjournal.com

 


 

Refer
A Friend

If you find the OTC Journal informative
and profitable, please forward our newsletter alert service to like-minded
friends and associates who share similar market interests.


Ensure
Newsletter Delivery

To ensure newsletter delivery, you
can add any additional email
addresses you may have to the OTC Journal Member List. Receiving the OTC
Journal Newsletter in multiple locations is the best way of making sure
you don’t miss the next investing or trading opportunity! For web based
email addresses, the OTC Journal recommends @yahoo.com or @aol.com for
timely and reliable email newsletter delivery.

Note: Your email address will
be kept strictly confidential, and will not be shared with any other entity
for any purpose at any time. If you no longer wish to receive the OTC Journal,
simply follow the instructions located at the bottom of every OTC Journal
Newsletter Edition.

 


 

 

Disclaimer
DISCLAIMER

The OTC Journal Newsletter is an
electronic publication committed to providing our readers with useful information
on publicly traded companies. The Newsletter contracts with publicly traded
companies and receives compensation from them in the form of cash and sometimes
restricted securities as payment for publishing information and opinion
about the company and the trading market for their securities. Principals
of the Newsletter may also purchase or sell securities of the companies
in the open market from time to time. The positions that the Newsletter
or its principals maintain in securities of the companies are disclosed
here (click
here
) and should be considered in making an investment decision regarding
these companies securities.  The Newsletter may be deemed to have
a conflict of interest between its open market activity and positions in
these securities and the timing of and opinions expressed in its publications
concerning these companies.  The publications should not be considered
to be independent publications concerning the company.

All statements and opinions expressed
herein are those of the editors and are subject to change without notice.
The Newsletter maintains editorial control over its publications and the
companies profiled therein do not have any editorial rights concerning
the information published about them. A profile, description, or other
mention of a company in the newsletter is neither an offer nor solicitation
of an offer to buy or sell any securities mentioned. While we believe all
sources of information provided by us and contained in our publication
to be accurate and reliable, we cannot and do not guarantee the accuracy
of information we received from third parties.

READERS  ARE ENCOURAGED TO DO
THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED IN
THIS PUBLICATION. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A
HIGH DEGREE OF RISK.

We encourage our readers to invest
carefully and read the investor information available at the web sites
of the Securities and Exchange Commission (“SEC”) at http://www.sec.gov
and/or the National Association of Securities Dealers (“NASD”) at http://www.finra.org.
We also recommend that you read the SEC advisory to investors concerning
Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm.
Readers can review all public filings by companies at the SEC’s EDGAR page.
The NASD has published information on how to invest carefully at its web
site.

The information found in this profile
is protected by the copyright laws of the united states and may not be
copied, or reproduced in any way without the expressed, written consent
of the editors of otcjournal.com.

 

You can unsubscribe
from this list at any time by Clicking
Here
. If you are having difficulty removing yourself or wish to change
your address please go to http://www.otcjournal.com/opt/?email=$subst(‘Recip.EmailAddr’).

Europe and Its Confederacy of Dunces

 

 

November 10, 2011
Volume
XIII, Issue 103

Home Page : www.otcjournal.com

Email Questions or Comments To:
editor@otcjournal.com
 

To: OTC Journal Members: 

Europe and Its Confederacy of Dunces

 

I’ve been kind of on the sidelines lately watching the developments in Europe and looking for signs the markets are shaping up. The market was down huge yesterday as Italian bonds are getting clobbered- meaning their short term interest rates are up, and their Government’s cost of borrowing is way up.

I’ve always admired the Italians. I don’t believe anyone can dispute the Italians have created many of the finest products in the world. The Italians make some of the finest wines, cars, glass, and fashions found anywhere on Planet Earth.

Italy, the epicenter of the Renaissance, has also created some of the greatest music and art the world has ever seen. This is the country that gave us Michelangelo and Leonardo DaVinci.

As if all that weren’t enough, Italy manages to shut the entire country down for the whole month of August. Everyone, except those in the tourist and service industries, stops working. Impressive. The way the markets have been since 2008, I’m lucky if I get a long weekend.

And, don’t get me started on the Greeks. Greece is one of the cradles of civilization. The Greeks invented Philosophy and Democracy. Most of the words in the English language can find their roots in ancient Greek.

So, how did these countries with such rich histories get themselves into such a mess? The stories out of Greece and Italy are absolutely trashing the markets now, and yesterday was another example.

Southern Europe is less prosperous and more troubled than Northern Europe, yet they are all bound by one currency. If the Italians and the Greeks could simply allow their currencies to fall dramatically, their goods and services would be more attractive to the rest of the world, and their respective GDPs could grow.

So, why is Europe descending into this giant mess? Well- it’s pretty simple, and super complicated at the same time. Let me give you the Reader’s Digest version. The Southern European countries are spending more than they are getting in tax revenues (sound familiar?).

There’s a possibility a number of European countries could actually go bankrupt- metaphorically speaking of course. If you’re bankrupt, you can’t pay your debts. Forget about paying off the debts- you can’t even pay the debt service.

This would have two major and immediate consequences. You won’t be able to bring in any new loans, so you won’t be able to support your quasi welfare states, and you’ll default on the amount you owe your bond holders.

So- who are these bond holders? They are the major European banks, who would then be improperly capitalized for a bank, and go down the toilet as well. Of course, this would create a run on the banks, and further downward you go.

One way out would be to let your currency devalue dramatically. But, there’s one currency for 17 nations. If the Euro gets clobbered, it would make Italian goods more attractive to International buyers, but the Germans would get less real money for their BMWs. Ouch.

It’s a bit of a mess, and the market responds to the headlines with violent moves one way or the other. The Confederacy of Dunces who are running Europe today are unbelievable. Here’s a little overview for your entertainment.

The Confederacy of Dunces

 

Meet George Papandreou- the future former Prime Minister of Greece.

Let me paint you a picture. You’re deeply in debt, you can’t generate the revenues to either service or pay off your debt.

Your neighbors and business partners don’t want to see you go down the tubes, so they offer to help. They offer to voluntarily cut all your debt in half, then they volunteer to write you a check for $140 billion so you have a little cash to tide you over.

Your neighbors and business partners walk away thinking they’ve done you a great service. I wish I had neighbors and partners like that- my financial life would be a lot easier.

Then, you tell those who have held out their hands and wallets in support that you “WANT TO THINK ABOUT IT”. In fact, you decide to do more than think about it. You decide to have a family gathering of all relatives- aunts, uncles, cousins, and the like get in on it.

You’re going to organize this family gathering as soon as you can get around to it, and let everyone vote.

This is exactly what the Greek Government decided to do. Instead of reaching for the life preserver, the Greeks want to think about it and have a nationwide referendum while they drown. Insane.

French politician Christian Estrosi nailed it when he was quoted as saying

“I want to tell the Greek Government that when you are in a situation of crisis, and others want to help you, it is insulting to try to save your skin instead of assuming your responsibilities”.

I couldn’t have said it better myself. Our political circus would be entertaining if it weren’t so scary, but these bozos take the cake. This is endless material for Saturday Night Live.

Taking the package was the hard thing to do because it came with austerity requirements, but it was the right thing to do. So, of course, the politician who’s heading the Greek Government didn’t have the you-know-whats to take the help because it might not have been popular with their welfare state.

So, Papandreou is now out as a result of his foolish and cowardly action. The Greek government is trying to figure out who is going to replace him, and there’s a lot of carrying on in Greek Parliament. It’s endlessly entertaining if it weren’t so troublesome for the markets.

So, so here’s our next big political winner.

Enter Silvio Berlusconi- head of the emergency government in Italy. This guy is something. He’s been elected Prime Minister 3 times and fired twice. He would never make it as a politician in the US with the powerful religious right having so much influence.

This guy has already been divorced twice, indicted for embezzlement and tax fraud, and has faced of 50 confidence votes in Parliament since 2008. His most recent exploit happened in January. Italian prosecutors are trying to get him to trial for paying for sex with a 17 year old Morrocan girl- Karina Keyek.

The news is Berlusconi will be out by Sunday, replaced with Mario Monti, a man seen as capable of restoring the national credibility and pushing through the austerity measures the world wants to see.

These are the characters running the European governments, and these are the politicians who are on their way out because they don’t have the political will to do what has to be done to save the European banking system from collapse.

Unlike the US in 2008 where, right or wrong, our government quickly developed a plan to save the banking system and avoid a Depression, Europe has many moving parts from various cultures, all with their own political agendas.

So, what really happened yesterday to cause a rout in the global markets? You won’t believe how innocent this seems. It is rumored a large Norwegian Oil fund decided to unload its Italian and Greek government bonds.

In the wake of the selling, the Italian 10 year note spiked to a 7.5% yield. The Italians cannot afford to pay more the 5% for funding in 2012. In order to stabilize the markets, the European Central Bank was buying Italian debt in huge quantities. Recently, Italy sold $5 billion in Euros at a 6.087% yield, and there was twice the demand for the bonds that were offered, so the market’s reaction was of course distorted.

It seems to me, while it is dragging out much longer than it would in the US, Europe can eventually implement a plan that will involve reduced spending by governments along with debt forgiveness and stimulus packages.

Don’t let the markets panic you on those violent days. The Europe saga will come out somewhere in the middle- not nearly as bad as the Bears would have you believe, but far from perfect.

It starts with getting rid of the Confederacy of Dunces that run those Southern European countries.


Tomorrow- an update on some of my still favorite stocks I’ve recently covered.


Home Page : www.otcjournal.com

Email Questions or Comments To:

editor@otcjournal.com

 


 

Refer
A Friend

If you find the OTC Journal informative
and profitable, please forward our newsletter alert service to like-minded
friends and associates who share similar market interests.


Ensure
Newsletter Delivery

To ensure newsletter delivery, you
can add any additional email
addresses you may have to the OTC Journal Member List. Receiving the OTC
Journal Newsletter in multiple locations is the best way of making sure
you don’t miss the next investing or trading opportunity! For web based
email addresses, the OTC Journal recommends @yahoo.com or @aol.com for
timely and reliable email newsletter delivery.

Note: Your email address will
be kept strictly confidential, and will not be shared with any other entity
for any purpose at any time. If you no longer wish to receive the OTC Journal,
simply follow the instructions located at the bottom of every OTC Journal
Newsletter Edition.

 


 

 

Disclaimer
DISCLAIMER

The OTC Journal Newsletter is an
electronic publication committed to providing our readers with useful information
on publicly traded companies. The Newsletter contracts with publicly traded
companies and receives compensation from them in the form of cash and sometimes
restricted securities as payment for publishing information and opinion
about the company and the trading market for their securities. Principals
of the Newsletter may also purchase or sell securities of the companies
in the open market from time to time. The positions that the Newsletter
or its principals maintain in securities of the companies are disclosed
here (click
here
) and should be considered in making an investment decision regarding
these companies securities.  The Newsletter may be deemed to have
a conflict of interest between its open market activity and positions in
these securities and the timing of and opinions expressed in its publications
concerning these companies.  The publications should not be considered
to be independent publications concerning the company.

All statements and opinions expressed
herein are those of the editors and are subject to change without notice.
The Newsletter maintains editorial control over its publications and the
companies profiled therein do not have any editorial rights concerning
the information published about them. A profile, description, or other
mention of a company in the newsletter is neither an offer nor solicitation
of an offer to buy or sell any securities mentioned. While we believe all
sources of information provided by us and contained in our publication
to be accurate and reliable, we cannot and do not guarantee the accuracy
of information we received from third parties.

READERS  ARE ENCOURAGED TO DO
THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED IN
THIS PUBLICATION. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A
HIGH DEGREE OF RISK.

We encourage our readers to invest
carefully and read the investor information available at the web sites
of the Securities and Exchange Commission (“SEC”) at http://www.sec.gov
and/or the National Association of Securities Dealers (“NASD”) at http://www.finra.org.
We also recommend that you read the SEC advisory to investors concerning
Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm.
Readers can review all public filings by companies at the SEC’s EDGAR page.
The NASD has published information on how to invest carefully at its web
site.

The information found in this profile
is protected by the copyright laws of the united states and may not be
copied, or reproduced in any way without the expressed, written consent
of the editors of otcjournal.com.

 

You can unsubscribe
from this list at any time by Clicking
Here
. If you are having difficulty removing yourself or wish to change
your address please go to http://www.otcjournal.com/opt/?email=$subst(‘Recip.EmailAddr’).